-online.com genomics





Human NAV2 CRISPR gRNA + Cas9 in Lenti Particles

| Overview | |
|-----------------------|--|
| Quantity: | 300 μL |
| Gene: | NAV2 |
| Species: | Human |
| Insert: | gRNA + Cas9 |
| Vector: | Lentiviral Vector |
| Application: | Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN) |
| Product Details | |
| Purpose: | Individual gRNA against NAV2 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and |
| | Cas9 in a single vector) |
| Vector Backbone: | pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro |
| Promoter: | U6 Promoter, SFFV Promoter |
| Selectable Marker: | Puromycin |
| Bacterial Resistance: | Ampicillin |
| Expression Type: | Stable, Transient |
| Sequence: | Sequence available upon placing order |
| Specificity: | GRNAs are designed for use with Cas9 Nuclease only. |
| | Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority |
| | of cells, except ES cells or iPS cells. |
| Sequencing Primer: | U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA3' |
| Components: | Lentiviral particles with an individual gRNA (300 µL) for a specific sequence of NAV2 |

Target Details

| Gene: | NAV2 |
|-------------------|----------------------|
| Alternative Name: | NAV2 (NAV2 Products) |
| NCBI Accession: | NM_001111019 |

| Application Details | | |
|---------------------|--|--|
| Application Notes: | Recommended for quality control: Restriction Enzyme Digest and Sequencing | |
| Restrictions: | For Research Use only | |
| Handling | | |
| Format: | Viral Particles | |
| Storage: | -80 °C | |
| Expiry Date: | 12 months | |
| Publications | | |
| Product cited in: | Johnson, Drugan, Miller, Evans: "38" in: . Vol. 1363. Issue Nucleic acids research, pp. 28-39. (| |

Product cited in: Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (
1991)